CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Elisa AgostinettoVéronique DebienGuilherme Nader MartaMatteo LambertiniMartine Piccart-GebhartEvandro de AzambujaPublished in: European journal of clinical investigation (2021)
Treatment landscape for HER2+ breast cancer is rapidly changing, and CDK4/6 and PI3K inhibitors represent a new promising strategy to improve patients' outcomes.
Keyphrases
- positive breast cancer
- end stage renal disease
- cell cycle
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- cell proliferation
- single cell
- adipose tissue
- big data
- skeletal muscle
- patient reported outcomes
- metabolic syndrome
- machine learning
- insulin resistance
- young adults
- artificial intelligence